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Vaginal concentrations of mannose-binding lectin (MBL) and
possession of a polymorphism in codon 54 of the MBL gene
were determined in 42 women with recurrent vulvovaginal
candidiasis (RVVC) and 43 control subjects. Reduced vaginal
MBL levels and an increased occurrence of the polymorphism
were present in women with RVVC.
Mannose-binding lectin (MBL) is a circulating protein and a
component of the innate immune defense system. It recognizes
and binds to mannose and N-acetyl-glucosamine residues on
the surface of microorganisms, resulting in complement acti-
vation. In addition, macrophages and dendritic cells contain
cell surface receptors that recognize MBL, facilitating opsoni-
zation of microorganisms with bound MBL on their surface
[1]. Reductions in serum levels of MBL have been associated
with opsonization defects [2] and with an increased risk of
recurrent infections in young children [3, 4].
The gene coding for MBL is polymorphic, and the decrease
in circulating MBL concentrations has been shown to correlate
with possession of mutant alleles in exon 1. Most studied is
the single nucleotide substitution of an adenine for a guanine
in codon 54 that results in replacement of aspartic acid for
glycine in the MBL protein [1, 5–7]. As a consequence of this
alteration, the assembly and stability of the final MBL protein
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is markedly reduced [5, 7]. Serum levels of MBL are ∼1.2–1.7
mg/mL in individuals who are homozygous for the wild-type
(guanine) allele, 0.3 mg/mL in individuals who are heterozygous,
and 10 ng/mL in individuals homozygous for the variant allele
(adenine) [6, 8]. The codon 54 substitution has also been shown
to be associated with an increased rate of infection [9, 10].
Candida species exhibit strong binding of MBL [11], sug-
gesting that this protein may be involved in immune defense
against candidal infection. This prompted us to examine cervi-
covaginal levels of MBL and MBL genotypes in women with
recurrent vulvovaginal candidiasis (RVVC). Women with RVVC
experience frequent episodes of a vulvovaginal Candida infection,
and the underlying mechanism responsible for this occurrence
remains unknown in many cases.
Methods. The study population consisted of 42 women
(age, 18–35 years) who had 4 culture-verified symptomatic
episodes of a vulvovaginal Candida infection during a 12-
month period and who currently had symptoms consistent with
a vaginal Candida infection (i.e., pruritis, burning, and abnor-
mal discharge) and a positive Candida culture. Control subjects
were 43 women who had no current gynecologic complaints,
who had no history of vaginal Candida infection, and who were
currently culture-negative for pathogens. All patients and con-
trol subjects were seen at the outpatient obstetrics/gynecology
department of Riga First Hospital in Riga, Latvia. Patients and
control subjects were matched for age, socioeconomic and mar-
ital status, and number of children. All were ethnic Latvians.
Exclusion criteria for this study were pregnancy, diabetes,
known immunodeficiencies, use of immunosuppressive med-
ications, or history of hysterectomy.
Informed consent was obtained from all subjects, and the
guidelines for human experimentation of the US Department
of Health and Human Services and Riga Stradin’s University
were followed in the conduct of clinical research.
Cervicovaginal samples were obtained by instilling 3 mL of
sterile saline into the posterior vaginal fornix, mixing with a
cotton swab, and then withdrawing the solution with a syringe.
An aliquot of each sample was cultured for Candida species
on Sabouraud’s medium and speciated by culture on CHROM
agar (CHROM Agar Candida Co.). Samples were also tested
for Trichomonas vaginalis, by wet mount; Chlamydia trachom-
atis, by PCR; Neisseria gonorrhoeae, by culture; HIV, by antibody
testing; and bacterial vaginosis, using the Amsel criteria [12].
The samples were centrifuged to obtain supernatant and pellet
fractions that were immediately frozen at 20C. Frozen sam-
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Table 1. Demographic and clinical characteristics of patients with recurrent






Age, mean years (range) 26.8 (18–35) 25.4 (18–35)
University education 21 (50) 16 (37.2)
Salary !$200 a month, % of subjects 38.1 60.5
Age at first sexual intercourse, mean years 19.6 18.4
Married 20 (47.6) 20 (46.5)
Smoker 12 (28.6) 9 (20.9)
Vaginal or vulvar erythema present 29 (69.0) 0
Abnormal vaginal discharge present 31 (73.8) 0
Vaginal fissures and/or excoriations present 24 (57.1) 0
Mean no. of pregnancies 2.4 2.3
Mean no. of children 1.1 1.0
History of spontaneous abortion 24 (57.1) 23 (53.5)
Candida infection
C. albicans 38 (90.5) 4 (9.3)
C. tropicalis 3 (7.1) 0
C. krusei 1 (2.4) 0
Bacterial vaginosis 10 (23.8) 0
NOTE. Data are no. (%) of subjects, unless otherwise indicated.
tious Diseases, Department of Obstetrics and Gynecology, Cor-
nell (New York) on dry ice for analysis.
The vaginal concentrations of MBL were determined using a
commercial ELISA (Cell Sciences) with a 1:5 dilution of the super-
natant fractions. The lower limit of sensitivity was 3.1 ng/mL.
DNA was extracted from the pellet fractions as described
elsewhere [13]. In brief, the pellets were thawed, washed, and
resuspended in a 1% solution of the nonionic detergent, Brij
35 in Tris buffer containing 5 mg/mL proteinase K. Cells were
lysed by incubation at 56C for 60 min, and the proteinase K
was then inactivated by increasing the temperature to 95C for
10 min. The lysed samples were diluted 1:5 in 10 mmol/L Tris-
HCl that contained 1.5 mmol/L of MgCl2; 50 mmol/L of KCl;
0.2 mmol/L each of deoxyadenosine triphosphate, deoxyctidine
triphosphate, deoxyguanosine triphosphate, and thymidine tri-
phosphate; 1.25 units of Taq DNA polymerase; and 30 pmol
of oligonucleotide primers that amplified the codon 54 poly-
morphic region of the MBL gene [14]. The final volume was
0.05 mL. Samples were incubated in a thermal cycler for 2 min
at 94C, followed by 35 cycles of 94C for 50 s, 58C for 1.5
min, and 72C for 15 s. Lastly, the samples were incubated at
72C for 5 min.
The PCR amplicons were then digested by incubation at 37C
for 18 h with Ban I endonuclease (New England BioLabs) in
buffer provided by the manufacturer. Fragments were analyzed
on 2% agarose gels and stained with ethidium bromide. Ban I
digestion resulted in either formation of two 260 and 89 bp
fractions (wild-type; allele A) or a single uncut 349 bp fraction
(mutant; allele B).
The relationship between genotype frequencies and diagnosis
was analyzed by Fisher’s exact test. Differences in median MBL
concentrations between patients and control subjects were an-
alyzed using the Mann-Whitney U test. The relation between
vaginal MBL levels and MBL genotype was analyzed by 1-way
analysis of variance and Tukey-Kramer multiple comparisons
test. was considered to be statistically significant.P ! .05
Results. Demographic and clinical characteristics of pa-
tients and control subjects are detailed in table 1. Candida
albicans was detected in 38 (90.5%) of the patients with RVVC,
Candida tropicalis was detected in 3 (7.1%), and Candida krusei
was detected in 1 (2.4%). Among the control women, 4 cultures
(9.3%) were positive for C. albicans. No other Candida species
were detected in the control subjects. Ten patients with RVVC
and none of the control subjects were positive for bacterial
vaginosis. All patients and control subjects tested negative for
T. vaginalis, C. trachomatis, N. gonorrhoea, and HIV.
The distribution of vaginal MBL protein concentrations in
patients with RVVC and control subjects is shown in figure 1.
The median MBL concentration in control subjects was 15.9
ng/mL (range, 10.1–84.1 ng/mL, compared with 7.3 ng/mL
(range, 2.9–18.7 ng/mL) for women with RVVC ( ).P ! .0001
The distribution of MBL alleles was significantly different in
control subjects and patients with RVVC ( ; table 2).P ! .0001
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Figure 1. Vaginal mannose-binding lectin (MBL) concentrations in women with recurrent vulvovaginal candidiasis (patients) and in control subjects
(controls). MBL concentrations in vaginal lavage samples obtained from patients and controls were determined by ELISA.
Table 2. Relation between mannose-binding
lectin (MBL) gene polymorphism and recurrent
vulvovaginal candidiasis (RVVC).
MBL genotype





AA 13 (31.0)a 39 (90.7)
AB 26 (61.9)b 4 (9.3)
BB 3 (7.1) 0 (0)
a .P ! .0001
b .P ! .0001
the wild-type allele (allele A), as opposed to only 31% of pa-
tients with RVVC. Conversely, almost 62% of patients with RVVC
were allele A/allele B heterozygotes, compared with only 9.3%
of control subjects. The frequency of allele B was 38.1% in
patients with RVVC, as opposed to 4.7% in control subjects
( ). Sixty-eight percent of the patients who were culture-P ! .0001
positive for C. albicans were either allele B heterozygotes or
homozygotes, 100% of the women positive for C. tropicalis were
allele B heterozygotes, and the single woman with C. krusei
infection was allele A homozygous.
Although the number of subjects is small, there was no re-
lationship between bacterial vaginosis and MBL genotype. Allele
A homozygotes, allele A/B heterozygotes, and allele B homo-
zygotes were present in 30%, 50%, and 20% of the patients
with bacterial vaginosis, respectively.
The relationship between vaginal MBL concentrations and
MBL genotypes is shown in figure 2. The median MBL level
in women who were allele A homozygous was 15.6 ng/mL
(range, 4.2–84.1 ng/mL). This was significantly greater than the
median level of 7.6 ng/mL (range, 4.5–17.3 ng/mL) in the A/
B heterozygotes and 2.9 ng/mL (range, 2.9–3.6 ng/mL) in the
B/B homozygotes ( ).P ! .0001
Discussion. Among Latvian women, RVVC was highly as-
sociated with carriage of the mutant codon 54 allele of the
polymorphic MBL gene. This allele was also associated with a
reduction in the vaginal concentration of MBL. Thus, this MBL
polymorphism appears to be one determinant of susceptibility
to RVVC in this population. The distribution of the different
MBL genotypes observed in the control group in the present
study paralleled the distributions noted by other investigators
who studied white, Asian, and Eskimo populations [6, 8, 15].
This validates the reliability of our assay and suggests that the
findings for these Latvian women may be applicable to other
populations of women with RVVC.
Asymptomatic colonization of the vagina with Candida spe-
cies occurs in ∼20%–30% of women of reproductive age [16].
In the present study, 9.3% of the control subjects had posi-
tive C. albicans culture results. The factors responsible for the
conversion of commensal Candida into a symptomatic path-
ogen at this site remain incompletely understood [17]. Th1
lymphocyte–directed cell-mediated immunity is the major de-
fense against Candida infections at mucosal sites [18], and IFN-
g, a Th1 cytokine, inhibits C. albicans yeast cells from under-
going germ tube formation [19]. In healthy women, production
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Figure 2. Relation between mannose-binding lectin (MBL) genotype and MBL concentrations in the vagina. A single base pair substitution in codon
54 of the MBL gene in women with recurrent vulvovaginal candidiasis and in control subjects was determined by PCR and endonuclease digestion
using primer pairs that spanned the polymorphic region. Vaginal MBL levels in patients and control subjects were determined by ELISA.
the recruitment and activation of phagocytic cells that ingest
Candida species. A variety of circumstances that result in pro-
duction of anti-inflammatory Th2-derived cytokines and pros-
taglandin E2 in the lower genital tract [20, 21] lead to a di-
minished capacity of the local cell-mediated immune system
to regulate Candida proliferation and the subsequent devel-
opment of clinical symptoms. RVVC results from a chronic or
periodic inability to induce a sustained Th1 immune response
against Candida species in the lower genital tract. If insufficient
to effectively promote Candida opsonization by phagocytes,
deficient vaginal levels of MBL may be a second overlapping
mechanism contributing to vaginal Candida proliferation in
women with RVVC. C. albicans was the major, but not the
only, Candida species isolated from the patients with RVVC.
The relative capacity of MBL to interact with these different
species remains to be determined. The present study did not
include women with a first episode of acute vulvovaginal can-
didiasis, so we are as yet unable to ascertain whether MBL
deficiency is related solely to RVVC or is a general feature of
symptomatic Candida vulvovaginal infection.
Similar to the situation in serum [6, 8], MBL concentrations
in cervicovaginal fluids also appear to vary according to the
individual’s MBL genotype. Although a direct comparison was
not attempted in the present study, it appears that the MBL
concentration in the lower genital tract is ∼80-fold less than
the concentration in serum. Most likely, MBL, which is syn-
thesized primarily in the liver, enters the female genital tract
as a transudate from the systemic circulation. MBL production
by murine epithelial cells was recently reported elsewhere [22].
Whether vaginal epithelial cells contributed to the MBL values
in the present study remains to be determined.
Not all women in the present study who had RVVC carried
the codon 54 B allele, although the level of MBL in their vaginas
was reduced. Polymorphisms at other exon 1 codons in the
MBL gene have been identified and are also associated with
reduced circulating MBL concentrations [5, 7, 14]. The rela-
tionship between variations at these other loci and RVVC re-
mains to be determined.
It is interesting to speculate whether periodic administration
of exogenous MBL or MBL-containing fluids would be an ef-
fective treatment to prevent the recurrence of Candida infection
in the vagina in women who carry the B allele. The present
investigation strongly suggests the potential usefulness of this
approach. This would be an improvement over the repeated
use of locally applied or systemic Candida-static drugs that are
currently prescribed for women with RVVC. There are 2 reports
on MBL infusions in humans with chronic diseases who were
MBL deficient [23, 24]. No adverse effects of exogenous MBL
administration were noted, and some clinical benefits were
apparent.
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